Novartis R&D spending by segment 2023

This statistic shows the expenditure on research and development of pharmaceutical company Novartis from 2017 to 2023, by business segment. In 2023, the company spent the highest amount within the given period, around 11.4 billion U.S. dollars, for research and development in the brand pharmaceuticals division.

Novartis AG's spending on research and development by segment from 2017 to 2023 (in billion U.S. dollars)

Characteristic	2017	2018	2019	2020	2021	2022	2023
Innovative Medicines	7.62	7.68	8.15	8.12	8.64	9.17	11.37
Sandoz	0.77	0.81	1.25	0.86	0.9	0.82	-
Alcon*	0.58	0.59	-	-	-	-	-

Loading statistic...

Download

Source

Show detailed source information?

Already a member?

Source

Use Ask Statista Research Service

Release date

January 2024

More information

Region

Worldwide

Survey time period

2017 to 2023

Supplementary notes

All figures are rounded.
* During 2019, eye care division Alcon was spun off and became an own company. Thus, Alcon's R&D expenses are not included from this year onwards.
** Due to the spin-off of Sandoz during 2023, there was no distribution of R&D spending by segment. The Innovative Medicines segment is now renamed to "Promoted brands".

Open this statistic in...

French

Citation formats